Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Allergan Aesthetics, an AbbVie company (NYSE:ABBV), received European Commission approval for Boey (trenibotulinumtoxinE).
Boey is described as the first rapid onset, short duration neurotoxin for the treatment of frown lines available in Europe.
This approval gives AbbVie a differentiated addition to its aesthetics portfolio in Europe, an area where the company already has an established presence. By targeting frown lines with a rapid onset profile and shorter treatment duration, Boey is aimed at patients looking for more flexible treatment schedules and faster visible effects.
For investors tracking NYSE:ABBV, the key point is how this new product could fit alongside existing facial injectable offerings and expand Allergan Aesthetics’ reach. The launch creates another reference point for AbbVie in the aesthetics segment as it seeks to compete on product features such as onset speed and treatment duration rather than only on brand recognition.
Stay updated on the most important news stories for AbbVie by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on AbbVie.
NYSE:ABBV Earnings & Revenue Growth as at Jul 2026
2 things going right for AbbVie that this headline doesn’t cover.
Quick Assessment
⚖️ Price vs Analyst Target: AbbVie trades at US$254.39 versus a consensus target of US$266.57, roughly 5% below, which sits inside the analyst range of US$200 to US$328.
✅ Simply Wall St Valuation: The stock is described as trading 44.1% below an estimated fair value, which screens as undervalued.
✅ Recent Momentum: A 30 day return of 14.3% shows strong short term positive momentum around AbbVie.
There’s only one way to know the right time to buy, sell or hold AbbVie. Head to Simply Wall St’s company report for the latest analysis of AbbVie’s Fair Value.
Key Considerations
📊 Boey’s approval gives AbbVie another product in European aesthetics that can broaden its revenue mix alongside the existing portfolio.
📊 Watch how management comments on Boey uptake, pricing, and margins in upcoming results and whether analyst targets shift from the current US$266.57 level.
⚠️ Simply Wall St flags four minor risks, including high debt and dividend coverage, so investors may want to weigh new product upside against these balance sheet and payout pressures.
Dig Deeper
For the full picture including more risks and rewards, check out the complete AbbVie analysis. Alternatively, you can check out the community page for AbbVie to see how other investors believe this latest news will impact the company’s narrative.